Aerie Pharmaceuticals to Present at Two Upcoming Investor Conferences

DURHAM, N.C.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced that Richard Rubino, Chief Financial Officer, will present an Aerie overview and provide a business update at two upcoming investor conferences:

• Raymond James Life Sciences and MedTech Conference
  • Date: Tuesday, June 18, 2019
  • Time: 9:45 a.m. ET
  • Location: New York, NY
  • Presentation Format: Corporate Presentation
• JMP Securities Life Sciences Conference
  • Date: Wednesday, June 19, 2019
  • Time: 3:00 p.m. ET
  • Location: New York, NY
  • Presentation Format: Fireside Discussion

The presentation and fireside discussion will both be webcast live and may be accessed by visiting Aerie’s website at http://investors.aeriepharma.com. A replay of each webcast will be available for 10 business days.

About Aerie Pharmaceuticals, Inc.

Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Aerie’s first product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. More information about Rhopressa®, including the product label, is available at www.rhopressa.com. Aerie’s second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa® and the widely-prescribed PGA (prostaglandin analog) latanoprost, has been approved by the FDA and was launched in the United States in the second quarter of 2019. In clinical trials of Rocklatan®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. More information about Rocklatan®, including the product label, is available at www.rocklatan.com. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema. More information is available at www.aeriepharma.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190611005016/en/

Media: Tad Heitmann 949-526-8747; [email protected]
Investors: Ami Bavishi 908-947-3949; [email protected]

Source: Aerie Pharmaceuticals, Inc.

You May Also Be Interested In

• How to Make Money With Crypto? LINK and XMR Catch Fire as Apeing’s September Presale Countdown Builds Major Hype 
• In HelloNation, Tax Expert Sal Julian Details Which Itemized Deductions High-Income Individuals Lose Without Knowing It
• ChowChow Cloud International Holdings Limited Provides Response to Unusual Market Action